Alps Group Publishes Peer-Reviewed Data Backing Safety of Novel NK Cell Therapy Platform

ALPS Group ( (ALPS) ) just unveiled an announcement.

On February 23, 2026, Malaysia-based Alps Group Inc reported peer-reviewed clinical data from a case series of nine patients treated between 2023 and 2024 with autologous Natural Killer cell infusions produced using its in-house culture protocol. The study, published in SAGE Open Medical Case Reports, showed clinical tolerability with monitoring of hematological, liver, inflammatory, hypersensitivity, and tumor markers, and was conducted under Malaysian Good Clinical Practice and the Declaration of Helsinki.

The company highlighted its patent-pending, antibody-free NK cell culture method, which uses basic media and autologous plasma to enable cost-effective, large-scale production of highly pure NK cells while improving safety and lowering manufacturing barriers. These preliminary safety findings, together with existing preclinical data, strengthen Alps Group’s positioning in scalable autologous immune cell therapies and are intended to guide future clinical investigations in broader patient populations.

More about ALPS Group

Alps Group Inc is the parent of Alps Life Sciences Inc., an integrated biotechnology platform combining research and development, medical services, and wellness solutions in advanced therapies. The group focuses on predictive, preventive, and precision medicine, aiming to make cutting-edge healthcare more accessible and affordable globally through a unified ecosystem model.

Average Trading Volume: 94,629

Technical Sentiment Signal: Sell

Current Market Cap: $150.6M

For an in-depth examination of ALPS stock, go to TipRanks’ Overview page.